A-Alpha Bio
Seattle
About A-Alpha Bio
A-Alpha Bio is a provider of cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio utilizes its proprietary AlphaSeq technology to map protein-protein interactions at a high scale and resolution. This technology can identify and quantify interactions between thousands of protein pairs simultaneously. By providing detailed maps of protein interactions, A-Alpha Bio aids in the identification of potential drug targets and the understanding of disease mechanisms. This can significantly streamline the process of discovering new therapeutics. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $64.1M
- Funding stage: Early Stage Venture
- Last round: Grant (May 2024)
- Website: aalphabio.com
- Phone: 8584057116
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/a-alpha-bio-41862 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.